|Year : 2017 | Volume
| Issue : 1 | Page : 22-35
Updates in vascular dementia
Nora Olazabal Eizaguirre1, Gerardo Priego Rementeria2, Miguel Ángel González-Torres1, Moises Gaviria3
1 Department of Psychiatry, Hospital Universitario Basurto, Bilbao; Department of Neuroscience, University of the Basque Country, Leioa, Bizkaia, Spain
2 Department of Psychiatry, Hospital Universitario Basurto, Bilbao, Spain
3 Department of Psychiatry, The University of Illinois at Chicago, Chicago, Illinois, USA
|Date of Web Publication||24-May-2017|
Nora Olazabal Eizaguirre
Pabellón Eskuza, Hospital Basurto, Avenida Montevideo 18, 48013 Bilbao, Bizkaia
Source of Support: None, Conflict of Interest: None
It has been more than a hundred years since Alzheimer and Binswanger's first description of vascular dementia (VaD). Ever since then, histopathology research and neuroimaging techniques have allowed the development of new pathogenic, etiologic, and treatment hypotheses. The “vascular cognitive impairment (VCI)” concept has also been developed, and it includes all grades of cognitive dysfunction of a vascular origin. Early detection of dementia as well as its primary prevention is the main goals for clinicians. For this reason, new scales, new diagnostic criteria, and preventive treatments have been proposed. The association between stroke and VaD is already known, but a comprehensive review of this relationship reveals a bidirectional causality. Depression has been hypothesized as a risk factor for later dementia development. Late-life depression is the most associated condition; however, studies have found it works as a prodromal state symptom. Deep knowledge in vascular risk factors that are involved in vascular origin cognitive decline is the most important prevention tool. Hypertension, Type II diabetes, cholesterol, and inflammation markers have demonstrated to increase the risk of VaD. Evidence supporting treatments for primary and secondary prevention of VaD and VCI are presented.
Keywords: Prevention, risk factor, vascular cognitive impairment, vascular dementia
|How to cite this article:|
Eizaguirre NO, Rementeria GP, González-Torres M&, Gaviria M. Updates in vascular dementia. Heart Mind 2017;1:22-35
| Introduction|| |
The first clinical description of vascular dementia (VaD) comes from Thomas Willis whose careful attention to the cerebral vasculature led to his description of the circle of Willis in 1684. Under the heading “A palsie often succeeds stupidity, or becoming foolish,” he describes: “I have observed in many that when the brain being first indisposed, they have been distempered with a dullness of mind, and forgetfulness, and afterward with a stupidity and foolishness, after that, have fallen into a palsie, which I often did predict.”
Otto Binswanger and Alois Alzheimer, in their clinicopathological correlations, separated dementia paralytica (neurosyphilis), a common disease at that time, from VaD and proposed the term “atherosclerotic brain degeneration” for the disease. Alzheimer wrote “New studies on senile dementia and brain diseases caused by atheromatous vascular diseases” in 1898, describing widespread atheromatosis of the vascular system, substantial brain weight loss, and dilated ventricles; relating these disturbances with VaD. Some years later, he described presenile dementia (Alzheimer's disease [AD]) after finding demented people with little vascular disease and a presence of neuritic plaques and neurofibrillary changes in their brains.,
In 1910, Emil Kraepelin divided the dementias into senile and presenile in his classification and including the term “arteriosclerotic dementia” among the senile dementias in his book “Psychiatrie.” The main conclusion was that cerebral arteriosclerosis or arteriosclerotic insanity was the most frequent form of senile dementia. Nowadays, AD is considered the most frequent cause of dementia.
VaD has been present in all versions of the Diagnostic and Statistical Manuals (DSMs): In DSM I (1951), it was called “chronic brain syndrome associated with senile brain disease;” in DSM II (1968), psychosis with cerebral arteriosclerosis; in DSM III (1980), it was classified as “multiinfarct dementia (MID).” In DSM IV, it was called “VaD.” Finally, in DSM V, the diagnosis is called “major neurocognitive disorder” specifying that it is due to vascular disease.
In 1970, Tomlinson examined the brains of demented and nondemented patients and concluded that arteriosclerotic dementia had been over diagnosed in the past and defined new pathologic features in the examined brains: cortical atrophy, ventricular dilatation, senile plaque formation, Alzheimer's neurofibrillary changes, etc.
V. Hachinski, in 1974, changed previous theories about the etiology of senile dementia and affirmed that it was small or large cerebral infarctions, and not cerebral atherosclerosis, the etiological cause of the mental deterioration. He proposed the term “MID” for this concept. He also noted that these cumulative strokes were sometimes symptomatic, but they could be silent and occur progressively. At that time, computed tomography (CT) and magnetic resonance (MR) were introduced and allowed the detection of noninfarction vascular changes such as white matter lesions (WMLs), small subcortical lacunae, and microhemorrhages.
Concept and terminology
A deepening knowledge and the development of new concepts in the field of dementia have led to the creation of different terms beyond “VaD” or “atherosclerotic dementia” used in older texts.
Nowadays, the most commonly used term for any cognitive disorder of a vascular origin is vascular cognitive impairment (VCI). VCI syndrome is a heterogeneous construct that includes VaD, mixed-origin dementia (AD and VaD), and “VCI, not dementia” (VCInD). VCInD is the term used for patients that, while suffering from cognitive deficits associated with vascular disease, do not meet criteria for the diagnosis of dementia. The VCI diagnosis also includes classical cerebrovascular disorders resulting in VaD: poststroke dementia, MID, and leukoaraiosis., Some authors have called this “the VaD spectrum,” and its main aim is to detect patients with a minimal cognitive impairment to prevent the development of dementia.
Mild cognitive impairment (MCI) is a cognitive decline greater than expected for a patient's age and education level, which does not interfere notably with their daily life activities. Even the concept's definition does not imply a specific outcome or an etiology; this term has been applied the most to the risk state of progression to AD. It was later demonstrated that AD is characterized by episodic and semantic memory loss, whereas VCI is associated with other signs of cognitive impairment such as executive dysfunction (an impairment in planning and execution of activities) also called nonamnesic MCI. Either way, the nonamnesic subtype of MCI and vascular origin MCI (VaMCI) can be included in the VCI concept.
Mixed dementias can include cerebrovascular disease with concomitant AD, Parkinson's disease, frontotemporal dementia or Lewy's Bodies disease. Vascular impairment can also contribute to cognitive decline in all kinds of neurodegenerative dementias. VaD can be the primary cause of dementia or an important contributing factor to the course of other types of dementias such as AD.
| Methods|| |
The main aim of this revision is to provide a concise and useful update on the topic of VaD, including its etiology, macroscopic and microscopic features as well as an overview from a diagnostic and clinical point of view.
A comprehensive search was performed on the Medline, Ovid, EMBASE, and PsycINFO databases using the terms “VaD” and “VCI.” From a total of 11,657 papers, those focusing on AD were excluded from the study, leaving 6964. The authors read the abstracts and looked for papers focusing on the “epidemiology,” “risk factor,” “pathogenesis,” “neuroradiology,” “neuropsychology,” and “treatment” topics. Original research, specific review articles, and consensus statements were analyzed, and the most relevant ones were used to extract updates.
| Epidemiology|| |
VaD is the second cause of dementia after AD. Population studies indicate that vascular risk factors (VRFs) increase the risk for suffering all types of dementia. Moreover, cerebrovascular lesions are present in most of the patients diagnosed with AD, and therefore mixed dementia (AD in patients suffering from cerebrovascular disease) could be considered the most frequent etiology leading to cognitive impairment.,
The Rotterdam study revealed a 6.3% prevalence of dementia in the general population, which increases exponentially from age 55–59 (0%–4%) to age 95 and over (43.2%). AD represents three-quarters of all dementia cases, while VaD accounts for 16%. European samples reveal a dementia prevalence between 5.9% and 9.4% for patients older than 65. Neurological Diseases in The Elderly Research Group found that 4.4% of the population was suffering from AD and 1.6% from VaD. The prevalences of both AD and VaD increase with age. The prevalence of AD doubles every 4.3 years while that of VaD does so every 5.3 years. Postmortem neuropathology studies are consistent with these results. The prevalence of VaD has been established as ranging from 1.2% to 4.2% in people over 65 years of age. Survival of patients suffering from VaD is shorter than that of AD patients because of the cerebrovascular and cardio VRFs as well as concomitant diseases.
Meta-analyses in this area reveal a big difference between studies regarding incidence and prevalence of VaD. The prevalence in dementia varies depending on the classification systems used (ICD, DSM IV, DSM III, etc.,), and on the diagnostic threshold selected in the spectrum of cognitive disorders. No homogeneous diagnostic criteria are used, and samples are of different education levels, incomes, countries, and ethnic groups., The general consensus among researchers is that the prevalence of VaD has been underestimated using specific, but not sensitive, clinical criteria.,,
The incidence of all-type dementia doubles every 5 years from ages 65–90, growing from 7/1000 at the age of 65 to 118/1000 in ages 85–89, according to the Framingham study. The 90+ study reveals the same rate of increasing incidence for patients of over 90 years of age.,
In studies comparing the AD and VaD's incidence rates, those for AD are higher (1.59/1000 person-years) than for VaD (0.99/1000 py). Other samples, such as the Canadian Study of Health and Aging reveal a VaD incidence rate of 3.79/1000 person-years by including deceased patients.
No consistent differences among races were found regarding the incidence and prevalence of dementia in population-based studies for any type of dementia,,, or for VCI. Stroke rates are higher in Asian countries, so VCI rates may also be higher.,
| Etiology|| |
Several studies have revealed that VRFs are common risk factors for AD, VaD, and related diagnoses (including VCI, MCI, and age-related cognitive decline). VRFs were thought to be at the origin of cerebral ischemia, and thus also at that of VaD, but studies have found that cerebral ischemia and amyloid deposits interact in a synergistic pathogenic mechanism so that VCI and AD occur together in mixed-origin dementias as well as in strokes. In the same way, VCI may unmask previously subclinical AD and other neurodegenerative processes. This relationship between VRFs and AD can be due to increased amyloid deposition in vascular injuries.,
VRFs are interesting in the efforts for dementia prevention as they are the only known modifiable risk factors. Type II diabetes, hypertension, cholesterol, and inflammation markers have demonstrated to increase the risk for dementia, AD, MCI, and cognitive decline.,,
Hypertension is the most studied risk factor  and has been linked to both an increased incidence (odds ratio [OR]: 1.59; confidence interval [CI]: 1.29–1.95) and increased prevalence of VaD (OR: 4.84; CI: 3.52–6.67). Both midlife and later-life hypertension have shown to increase the risk for VaD although the relationship between long-standing hypertension during the midlife and VaD is the strongest., Late-life hypotension has also been identified as a risk factor for dementia development, showing a U-shaped relationship with systolic arterial pressure.
Hypertension affects blood vessels' elasticity over the long-term, leading to atherosclerotic changes that diminishes the capacity of the vessels to respond to changes in irrigation requirements in the brain., Preventive treatment of hypertension with antihypertensive agents in patients older than 60 has revealed a risk reduction for developing dementia of 55%. The benefits of antihypertensive treatment in patients already exhibiting cognitive impairment remain unclear.
Neuropathologic studies have revealed that diabetes doubles the risk for developing dementia, AD and VaD as well as increases mortality in elderly patients. Diabetes mellitus during the midlife has been associated with an increased risk for developing dementia three decades later (OR: 2.83; CI: 1.40–5.71). Inadequate glycemic control is associated with cognitive decline affecting psychomotor speed and efficiency. Hemoglobin Ac1 levels in nondiabetic patients have also been linked to cognitive impairment.,
Dyslipidemia is associated with atherosclerotic vascular disease and dementia. Increased low-density lipoprotein levels and decreased high-density lipoprotein levels have been linked with higher rates of atherosclerotic vascular disease and dementia. Midlife high total cholesterol levels are associated with an increased risk of all types of dementia. Adherence to a mediterranean diet is associated with a lower incidence of cognitive impairment in a large population-based study (REGARDS), especially in nondiabetic individuals. Some studies have hypothesized the benefits of taking preventive statins for hyperlipidemic and nonhyperlipidemic patients to diminish the risk for developing dementia. Recent placebo-controlled prospective studies conclude that the effect of statins in the incidence of dementia is negligible.
Blood inflammatory markers, serum C-reactive protein (CRP), serum interleukin 6, and plasma alpha-1-antichymotrypsin have been linked to the risk of developing dementia. Hyperhomocysteinemia is associated with AD, but there is no evidence to link it to VaD.,,
Demographic factors such as race and sex have not revealed clear results; it was commonly thought that men would show a higher incidence of VaD, and that people of black race would exhibit higher rates of VaD, but the evidence for these associations remains unclear.,
Genetic factors include nonmodifiable risk factors, such as Apolipoprotein E4 (APOE4). APOE4 has been linked to increased cardio VRFs and is also strongly associated with AD.,
Low educational level and sedentary habits have been found to be associated to higher rates of VaD. Heavy alcohol consumption and cigarette smoking have been linked to cognitive decline.,,, Obesity during the midlife is linked to VaD, and a higher waist-hip ratio increases the risk as well. However, in later life, obesity appears to be a protective factor for cognitive impairment and presents a U-shaped relationship.
Patients suffering from moderate and severe chronic kidney disease have an increased the prevalence of cognitive impairment, even for those patients that are under adequate dialysis treatments., Coronary artery disease and atrial fibrillation are independent risk factors for VaD as well as for all other types of dementia., Peripheral arterial disease as measured by the Ankle–Brachial Index is associated with an increased risk of VaD. Cardiac dysfunction and cerebral hypoperfusion as measured by the Cardiac Index have shown a relationship with accelerated brain aging in the Framingham heart study.
Risk factors for VCI and VaD are similar to those for stroke and have been classified into demographic, atherosclerotic, genetic, and stroke-related factors as shown in [Table 1]., Evidence for VCI prevention as well as treatment options are summarized in [Table 2].
|Table 2: Differential features of Alzheimer disease and vascular dementia|
Click here to view
Poststroke dementia occurs in 20%–30% of patients who have had a stroke,,,, 51% of them being diagnosed with VaD or mixed VaD-AD (37%), showing no gender differences., Cognitive deficits are observed in 10%–82% of these patients, depending on the evaluation method and diagnostic criteria used., VCI is seen in 45.1% of the patients who suffer from a stroke, and it develops more frequently in patients with low education levels, those who suffer from strategic strokes, those that exhibit greater white matter changes, and in those whose strokes are moderate to severe., The risk is higher for patients suffering from concurrent illnesses that determine a poststroke cerebral hypoxia or ischemia, such as cardiac arrhythmias or seizures.,, Some other risk factors for the subsequent development of dementia are a prior stroke (OR 3.1), a left carotid vascular territory location (OR: 12.5), an age higher than 65 years (OR: 6.6), a low education level (OR: 3.3), and a previous low functional state (OR: 4.5). Recurrent strokes seem to be the strongest risk factor for long-term cognitive decline. Life expectancy is affected in poststroke dementia mainly due to the increased risk of cardiovascular mortality and stroke recurrence.
Having a previous cognitive impairment diagnosis is associated to a 2-fold increase in the risk of suffering a stroke. This observation lends credibility to the hypothesis that VCI is a manifestation of vascular brain injury., Nevertheless, having a previous diagnosis of AD is not considered a risk factor for subsequent stroke.
Subclinical or silent brain infarctions seen in MR images (MRIs) are also considered a risk factor for later cognitive impairment; these patients exhibit a doubled risk of dementia in the subsequent 5 years of follow-up.
Depression and dementia are common pathologies among elderly individuals. The previous histories of depressive symptoms and higher rates of dementia have been observed for both VaD and AD.,, The complex relationship between depression and dementia has been studied through different hypotheses: depression as risk factor, depression as a prodromal stage of dementia, or considering them as two different and concomitant pathologies.
The underlying mechanisms that have been hypothesized to be responsible for such a high concurrency are cerebrovascular pathology, such as WMLs, monoamine deficits, inflammatory activity, and corticosteroid-related disturbances. These studies have not revealed consistent findings that would allow to elucidate with certainty the common neurobiological mechanisms., Depression is common in patients after suffering a stroke, and longitudinal studies have found prevalence rates of 31.7% that remain high even 10 years after the event. The rate of depression is higher among patients with prestroke dementia.
Late-life depression (LLD) and early life depression (ELD) have been studied in longitudinal studies as risk factors for developing later dementia. A history of either LLD or ELD has been found to be associated to a 3-fold risk of VaD. ELD by itself is not clearly linked with later dementia development, with contradictory results in different studies. On the other hand, LLD could be understood as a prodromal phase, or an early manifestation of dementia, due to the strong temporal association, especially with VaD.,, The evidence of a link between depression and the incidence of MCI is contradictory;,, however, there is evidence for a link between depression and prevalent MCI. Some studies have demonstrated higher dementia rates in patients suffering from more severe and frequent depressive episodes.,, LLD and VaD have both demonstrated a higher prevalence of WMLs, suggesting a common neuropathologic mechanism, with WML being responsible for the persistence of cognitive deficits following a depressive episode.,, This common neurovascular etiology  is supported by the studies that found a higher risk of stroke in elderly patients suffering from depression.
Cognitive performance is affected in both dementia and depression, but a temporal relationship between incident depression and dementia has not yet been demonstrated., Patients suffering from LLD exhibit a slowed processing speed and disturbances in executive function. Depression in patients suffering from dementia has demonstrated to accelerate cognitive decline.
Antidepressant treatment has not proven efficacious in people suffering from depression with a the previous diagnosis of dementia. Most studies have not found antidepressant agents to be more effective than placebo for this condition.
Neuropathology and neuroradiology
The diagnosis of VaD is mainly clinical as radiologic criteria alone are not enough for the diagnosis of VaD or VCI. Some diagnostic criteria such as NINDS-AIREN include neuroradiological findings as a key element for the diagnosis of VaD. Moreover, clinical and imaging findings do not need to coincide in their anatomical locations.,,
MRI is more sensitive than CT in the detection of cerebrovascular disease. Newer technological advances such as 7 Teslas MRI have shown an even greater sensitivity and represent a hopeful demonstration for the future as tools that may allow for the early detection of small vessel lesions in microinfarctions and microhemorrhages.
Small vessel disease
The term leukoaraiosis or WMLs are a descriptive term introduced in 1987 by Hachinski et al. to indicate the periventricular white matter MR hyperintensities frequently found in elderly people. It is a nonspecific radiological finding that may be present in both normal and demented populations. WMLs are associated with cerebrovascular disease and nonvascular pathology such as demyelinating disorders, infections, and neoplasic processes. Cerebral hypoperfusion and ischemia are purported to be responsible for WML in patients with VRFs or suspected of suffering from VaD.
WMLs are linked to old age and hypertension and are more frequent in patients suffering from stroke, for both symptomatic and nonsymptomatic ischemic strokes., In research like the Framingham study, a high inheritability in the accumulation of WML has been found.
The relationship between WML in neuroimaging (TC and MR) and dementia is controversial. Patients exhibiting WMLs have alterations in some cognitive domains such as executive function and processing speed but may not fulfill the dementia diagnosis criteria. It has been suggested that a certain volume of WML correlates with cognitive impairment; however, further studies are needed to determine the threshold.
WML location is an important factor that influences the severity of cognitive impairment; periventricular lesions have demonstrated greater association with cognitive decline over subcortical WML. This phenomenon has been explained by WML close to the cerebral ventricles damaging periventricular long association fibers, resulting in cholinergic denervation in the cerebral cortex. WMLs appear as hypodense (dark) on CT, hypointense (dark) on T1-weighted MRI, and hyperintense (bright) on T2-weighted MRI sequences. The Fazekas scale was developed to unify criteria and measure white matter changes and basal ganglia lesions in both CT and MRI. Interrater reliability for CT is moderate for CT (Ҡ = 0.48) and good for MRI (0.67) with different sensitivities for specific cerebral regions [Figure 1].,
Lacunes are subcortical small artery infarctions measuring up to 10 mm and affect the caudate, thalamus, internal capsule, cerebellum, and brainstem., Several studies suggest that SVD in the form of silent lacunes correlates to poorer executive functioning., This is consistent with the hypothesis that small vessel disease (SVD) disrupts frontal-subcortical circuits. Lacunes visible in MRI may also have important implications for the successful execution of activities fundamental to the maintenance of an independent lifestyle, due to their association with executive dysfunction. Large numbers of lacunes located in gray matter are referred to as “état lacunaire” or “status lacunaris;” and it is called “éstat criblé” or “status cribosus” if the location is in white matter. MRIs of lacunes are hyperintense on T2 and fluid-attenuated inversion recovery (FLAIR).
Silent cerebral infarctions are strokes which occur without focal neurological or classical signs or symptoms. They present with subtle cognitive function disturbances that can go unnoticed. The presence of silent infarctions doubles the risk of dementia. These silent infarctions are common in the nondemented elderly population, with 8%–28% of the population exhibiting them in neuroimaging. Infarction anatomic location and disrupted white matter connections are the key matters that determine the functional impact of silent infarcts.
Large vessel disease
Single or multiple infarctions (MID) are caused by the occlusion of large and medium-sized arteries such as the internal carotid artery, mild cerebral artery, or proximal perforating arteries. VaD may develop depending on the location and the volume of the affected brain parenchyma. CT angiography and MR angiography are very sensitive in revealing the size and the location for both symptomatic and asymptomatic strokes. MR reveals hyperintensity in T1 and FLAIR images. Thalamic infarctions must be especially taken into account because of the peculiar form of VaD that develops from them, leading to slowness, apathy and impairments in attention, motivation, and initiative.
Watershed infarctions occur in the distal areas of major cerebral arteries, in the border regions between two or three main cerebral arterial territories. The etiology is still controversial, but systemic hypotension, cardiac arrest, internal carotid artery occlusion, and emboli are known to cause them., Cortical watershed infarctions, located in the lateral margins of the lateral ventricle, are hyperintense in MR. Internal watershed infarctions are also hyperintense, running parallel to the lateral ventricles.
Global cerebral hypoperfusion is often found in patients with cardiac dysfunction and large artery disease; cardiac arrest, profound hypotension, and large vessel atherosclerosis are good examples. Vessels in the circle of Willis and carotid arteries degenerate in the presence of VRFs, such as hypertension or dyslipidemia, and correlate with high dementia rates., Atherosclerosis can lead to white matter hypoperfusion, WMLs, and diffuse white matter changes. Chronic hypoperfusion can also lead to brain atrophy and hippocampal neuronal loss.,
The role of cerebrovascular disease has further implications than just VaD. It may regulate the clinical expression of dementia caused by other underlying factors, including AD., Pathophysiological studies have revealed that neurons, glia, and vascular cells are synergistically responsible for the alterations in cerebral blood vessels and neuronal dysfunction that leads to cognitive impairment.,
The main responsible mechanisms of brain tissue damage are described below:
- Deep white matter is vulnerable to vascular insufficiency due to its location at the distal border between vascular territories. Reduced blood flow has been linked with leukoaraiosis areas and reduced vascular reactivity., White matter is susceptible to damage during blood pressure fluctuations. This impaired cerebrovascular self-regulation is thought to precede WMLs and to be responsible for them. A lowered cerebral blood flow can be observed before the onset of the clinical features of dementia. An impairment of nitric oxide-dependent vasodilatation and a greater rigidity in large vessels have been suggested as the mechanisms responsible for reduced blood flow and vascular reactivity in large vessels ,
- Blood–brain barrier (BBB) permeability is altered due to endothelial dysfunction, especially in WML areas., This BBB dysfunction could even precede white matter injury. Endothelial cells are damaged following ischemia and hypoxia. Oxidative stress and vascular inflammation can alter BBB permeability 
- Oxidative stress, free radicals, and inflammation are observed in the damaged white matter in patients suffering from VCI. VRFs are associated to vascular oxidative stress and inflammation, and functional hyperemia, as well as endothelium-dependent responses, are attenuated in these patients. Free radicals affect angiotensin II leading to the impairment of neurovascular coupling, which affects the neuronal activity-induced cerebral blood flow functional increase 
- BBB alterations lead to the extravasation of plasma proteins (fibrinogen, inmunoglobulins, and complement), which can activate inflammation and free radical production. Neurons and glia have a prosurvival and protective effect on endothelial cells. Free radicals and inflammation reduce brain-derived neurotrophic factor levels, which leads to a negative trophic effect on vascular cells, leading to endothelial cell atrophy, and microvascular rarefaction. Capillary density is reduced in damaged tissue; however, it is also reduced in apparently normal white matter in patients with VCI. Vessels that lack an endothelium are also observed. These processes are thought to be related to brain volume loss 
- Axon myelination allows for faster neural conduction and reduced energy expenditure in white matter tracts. Pro-inflammatory environments lead to demyelination with two main consequences: the slowing of axonal potential transmission, and axonal loss., Connections between deep white matter, thalamus, and the forebrain cholinergic neuronal system can be damaged, with executive dysfunction being the major consequence.,
The kind of vascular lesions that lead to VCI are diverse. Cognitive decline is commonly associated with widespread small ischemic vascular lesions involving subcortical brain areas (the basal ganglia and hemispherical white matter). Leukoaraiosis is the term used to describe these confluent WMLs. The main mechanisms involved are as follows: (a) atherosclerotic plaques affecting small cerebral vessels, (b) lipohyalinosis affecting the vascular walls, (c) the stiffening and microvascular distortion (arteriolosclerosis), and (d) fibrinoid necrosis.
Microinfarctions and microhemorrhages are usually associated with leukoaraiosis, lacunar infarctions, large infarctions, and hemorrhage., Furthermore, stenosis of the internal carotid arteries is associated with chronic ischemia and cognitive impairment. Systemic factors affecting global cerebral perfusion such as cardiac arrest, cardiac failure, arrhythmias, or hypotension have also been related to transient or permanent cognitive impaired function.,
Cognitive impairment in VaD is heterogeneous, potentially affecting almost all of the cognitive domains. Two different clinical patterns have been recognized depending on the predominant pathology and clinical symptoms: the cortical and subcortical VaD subtypes.
In the cortical VaD, clinical features are specific to affected anatomic areas as seen in strokes. Pathology involving the frontal lobe leads to executive dysfunction, apathy, and abulia. On the other hand, dominant temporal lesions induce aphasia, apraxia, and agnosia whereas nondominant lesions lead to anosognosia, confusion, and visuospatial difficulties. Anterograde amnesia is seen when the medial temporal lobe is affected. The onset of these clinical features is not typically abrupt but insidious and progressive. Subcortical dementia has been largely studied in terms of its pathophysiology and clinical aspects, and it has been associated to small vessel disease in subcortical areas. Pathophysiological studies have identified two further different types of subcortical vascular dementia: Binswanger disease with extensive WML in subcortical white matter regions; and the multiple lacunar infarction subtype., Both subtypes affect the deep cerebral nuclei and white matter pathways, disrupting connections with remote cortical areas such as the frontal lobe. Gait disturbances, urinary symptoms, apathy, abulia, depression, and psychomotor retardation are the typical clinical features in patients suffering from subcortical vascular dementia.
VaD biomarkers can be found in both serum and cerebrospinal fluid (CSF) of patients. The purpose of the study of these biomarkers is to facilitate the differential diagnosis of different dementia subtypes and to help in the development of early detection and treatment strategies.
CSF biomarkers have great sensitivity and low specificity for VaD based on the presence of proteins that indicate increased BBB permeability (serum/albumin ratio, total protein, etc.). These are not specific for VaD and can be present in AD as well. The matrix metalloproteases (MMP) are thought to respond to changes indicating inflammation in extracellular matrix. Elevated MMP levels are associated to demyelination phenomena in VaD. Serum-CSF folate ratio is lower in VaD patients than in those suffering from AD.
Serum and plasma biomarkers for VaD include inflammation biomarkers such as hyperhomocysteinemia and CRP. Lipoprotein-A is related to atheromatosis process and subsequently to VaD. Similarly, indicators of cerebral thrombosis such as D-dimer, thrombin, etc., are associated to VaD.,
Genetic factors are known for some vascular diseases, such as CADALSIL. AD and VaD have some causal pathways in common including, presenilin, amyloid, and APOE.
Polymorphism in angiotensine receptors have been linked to VaD. Genes involved in inflammation cascades are possible future investigation targets.
These prodromal indicators show promise as potential targets for the prevention of progression of VaD.
| Diagnosis|| |
The differential diagnosis between AD and VaD, as well as the early detection of cognitive disturbances, such as VCI, is the main objectives of all the diagnostic criteria and diagnostic scales proposed for VaD. The differential features for AD and VaD are summarized in [Table 1]., There is a lack of satisfactory diagnostic criteria for VCI and most of the definitions used for the diagnosis of dementia include memory loss, but executive dysfunction remains the most typical feature of vascular-origin cognitive disorders, showing memory loss only in the more severe stages.
Hachinski published in 1974, the original Hachinski Ischemic Score (HIS), provided criteria for the differential diagnosis of VaD from AD., Patients scoring 7 or more in the (HIS) are labeled as VaD and patients scoring lower than 4 are labeled as AD. Patients with scores between 5 or 6 are considered mixed dementias [Table 2].
The most relevant clinical diagnostic criteria are presented in [Table 3]. The patient classification has been revealed to have low correlation rates across the different available diagnostic criteria.,,, Different classification systems identify the same size samples, but results reveal low-reliability rates measured by the Kappa index.,
The Hachinski Ischemic Scale does not include any neuroimaging criteria. HIS performs well for differential diagnosis between VaD and AD, with a sensitivity and specificity near 0.9. Mixed dementias are more problematic. Interrater reliability has been established as 0.61 of K value.
In the NINDS-AIREN criteria, memory impairment is needed to diagnose dementia, leading to a diagnostic overlap with AD and mixed dementias. These criteria have demonstrated a high specificity for the diagnosis of VaD, but a low sensitivity is its biggest drawback., The NINDS-AIREN criteria are nowadays the most widely used diagnostic criteria for research.
The American Stroke Association-American Heart Association (ASA-AHA) criteria are thought to be more sensitive than NINDS-AIREN's because they do not require memory loss and require fewer impaired cognitive domains. There are not any clinical, pathologic studies available to reach any conclusions about sensitivity and specificity of the ASA-AHA criteria.,
The principal aim of neuropsychological assessments is to distinguish between AD and VaD, but a high prevalence of mixed dementias lowers the specificity of all the available neuropsychological tests. Furthermore, neuropsychological profiles are heterogeneous among patients suffering from VCI, with a typical expression including executive dysfunction and psychomotor slowing., The clinical manifestations of this frontal executive dysfunction are due to the early involvement of cortico-subcortical circuits and include impaired attention, difficulties in planning of complex activities, as well as disorganized thought, emotions, and behavior., The specific tasks for executive dysfunction should assess working memory, abstraction, reasoning, mental flexibility, and fluency.,
Patients with VCI show a greater retention of new information and lower rates of forgetting as compared to AD patients, but they exhibit higher rates of disturbances on visual memory and encoding new information., Patients suffering from VaD show disturbances in verbal memory tasks; however, this change is not applicable to patients with VCI. Regarding subjective perceived cognitive dysfunction complaints, patients suffering from VaMCI have shown higher frequency of complaints than patients suffering from other types of MCI, reinforcing the idea that vascular origin cognitive impairments are different in their clinical profile.
The mini-mental state examination (MMSE) test, the most widely used bedside test for the screening of dementias, is not sensitive in distinguishing between AD and VaD; cortical functions such as language, calculation, and orientation tend to be relatively preserved in VaD, and executive functions are not included in MMSE. The Montreal Cognitive Assessment (MOCA) achieves a more comprehensive assessment of major cognitive domains and includes executive functioning tasks with a good discriminant validity, resulting in a higher sensitivity and specificity., The Neuropsychiatric Inventory was developed in 1994 by Cummings and focuses the attention on the behavioral disturbances in dementia classified in 10 domains (apathy, anxiety irritability…) and assesses a wider psychopathology than tests centered in memory., The NINDS-AIREN working group has proposed the shortened version of MOCA for the screening of VaD which includes 12 items. Three subtests have been selected: A six-item orientation task, a five-word immediate and delayed recall task, and a phonemic fluency test.,
Functional scales can also be useful to assess instrumental and self-care activities in daily living. The Activities of Daily Living Questionnaire (ADLQ) measures the functioning in six areas (employment, self-care…). ADLQ has demonstrated accurate detection of temporal decline in patients with probable dementia.
| Prevention and Treatment|| |
The primary prevention of VCI aims to achieve the control of known risk factors. VRFs are modifiable, and their control has demonstrated efficacy in preventing VCI [Table 4]. Secondary prevention has two main objectives: an early diagnosis and treatment of acute stroke, and the prevention of stroke recurrence.,,
Currently, there are no Food and Drug Administration - approved drugs for the treatment of VaD. Two-thirds of stroke survivors suffer from behavioral and cognitive changes such as depression, apathy, and intellectual decline, but few stroke trials include cognitive and behavioral end-points for the evaluation of new treatments.
Cholinesterase inhibitors may be useful in VaD. Subcortical cerebrovascular disease may disrupt cholinergic pathways from nucleus basalis of Meynert. Cholinesterase inhibitors increase the amount of acetylcholine at the synapse gaps, possibly overriding the disruption caused by CVD;, however, large clinical trials show inconsistent benefits, and the available data shows beneficial effects in mixed VaD-AD. Donepezil has been studied in the largest clinical trial of pure VaD to date, and statistically significant improvements were found in cognitive function. Galantamine has not demonstrated major improvements in daily living activities in patients with probable VaD. Rivastigmine and memantine have shown improvements in cognitive and behavioral areas, but further studies are needed.,
Patients treated with nimodipine demonstrated an improved performance on lexical production and showed less deterioration on the MMSE and the Global Deterioration Scale. Poststroke-administered actovegin has shown an improved functional recovery and reduced neurological deficits as measured in Global Impression-Schizophrenia, MMSE, and other cognitive scales. There is no current evidence for aspirin in VaD; however, the Aspirin in Reducing Events in the Elderly study is still underway.
Cerebrolysin administered in poststroke patients has contradictory results in trials that have tried to demonstrate improvement in clinical global improvement, cognitive performance, and the activities of daily living. The intensive management of preexisting risk factors such as homocysteine levels has demonstrated some benefits. Fasting total homocysteine is an independent predictor of cognitive decline. Elevated homocysteine is a marker of folate/B12 deficiency; significant improvement in cognition has been shown after supplementation in patients with mild to moderate all-type dementia.
| Conclusions|| |
VCI as a complex clinicopathological entity is the second leading cause of dementia nowadays. Vascular origin cognitive impairment acts synergistically with other causes of dementia, giving rise to what is known as “mixed dementias.” The most often used diagnostic criteria show a low diagnostic concordance between them, and available screening tests fail to take into account dominions that characterize VaDs, being above all centered in evaluating memory. As of the writing of this paper, there are not any approved treatments, and therefore, efforts should be focused on primary prevention by controlling cardio VRFs. Because of all of this, vascular origin cognitive impairment is an entity on which further research and robust conclusions are still sorely needed.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Willis T, Philiatros E. The London Practice of Physick.London: Classics of Medicine Library; 1992.
Binswanger O. Die Abgrenzung der allgemeinen progressiven Paralyse. Berl Kli Wochenschr 1894;31:1180-6.
Alzheimer A. Neuere Arbeiten über die Dementia senilis und die auf atheromatöser Gefässerkrankung basierenden Gehirnkrankheiten. Eur Neurol 1898;3:101-15.
Binswanger O. Zur Klinik und pathologischen Anatomie der arteriosklerotischen Hirnerkrankung. Dtsch Med Wochenschr 1908;50:2199.
Fratiglioni L, Launer LJ, Andersen K, Breteler MM, Copeland JR, Dartigues JF, et al.
Incidence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000;54 11 Suppl 5:S10-5.
Association AP. Diagnostic and Statistical Manual of Mental Disorders (DSM-5®
). Washington, DC: American Psychiatric Publishing; 2013.
Tomlinson BE, Blessed G, Roth M. Observations on the brains of demented old people. J Neurol Sci 1970;11:205-42.
Hachinski VC, Lassen NA, Marshall J. Multi-infarct dementia. A cause of mental deterioration in the elderly. Lancet 1974;2:207-10.
Hachinski V. Vascular dementia: A radical redefinition. Dementia 1994;5:130-2.
Hachinski V, Iadecola C, Petersen RC, Breteler MM, Nyenhuis DL, Black SE, et al.
National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke 2006;37:2220-41.
Moorhouse P, Rockwood K. Vascular cognitive impairment: Current concepts and clinical developments. Lancet Neurol 2008;7:246-55.
Erkinjuntti T, Román G, Gauthier S, Feldman H, Rockwood K. Emerging therapies for vascular dementia and vascular cognitive impairment. Stroke 2004;35:1010-7.
Rockwood K, Howard K, MacKnight C, Darvesh S. Spectrum of disease in vascular cognitive impairment. Neuroepidemiology 1999;18:248-54.
Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, et al.
Mild cognitive impairment. Lancet 2006;367:1262-70.
O'Brien JT, Erkinjuntti T, Reisberg B, Roman G, Sawada T, Pantoni L, et al.
Vascular cognitive impairment. Lancet Neurol 2003;2:89-98.
Ganguli M, Fu B, Snitz BE, Hughes TF, Chang CC. Mild cognitive impairment: Incidence and vascular risk factors in a population-based cohort. Neurology 2013;80:2112-20.
Román GC. Facts, myths, and controversies in vascular dementia. J Neurol Sci 2004;226:49-52.
Román GC. Vascular dementia may be the most common form of dementia in the elderly. J Neurol Sci 2002;203-204:7-10.
Korczyn AD, Vakhapova V, Grinberg LT. Vascular dementia. J Neurol Sci 2012;322:2-10.
Ott A, Breteler MM, van Harskamp F, Claus JJ, van der Cammen TJ, Grobbee DE, et al.
Prevalence of Alzheimer's disease and vascular dementia: Association with education. The Rotterdam study. BMJ 1995;310:970-3.
Berr C, Wancata J, Ritchie K. Prevalence of dementia in the elderly in Europe. Eur Neuropsychopharmacol 2005;15:463-71.
Lobo A, Launer LJ, Fratiglioni L, Andersen K, Di Carlo A, Breteler MM, et al.
Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000;54 11 Suppl 5:S4-9.
Knopman DS, Parisi JE, Boeve BF, Cha RH, Apaydin H, Salviati A, et al.
Vascular dementia in a population-based autopsy study. Arch Neurol 2003;60:569-75.
Hébert R, Lindsay J, Verreault R, Rockwood K, Hill G, Dubois MF. Vascular dementia: Incidence and risk factors in the Canadian study of health and aging. Stroke 2000;31:1487-93.
Wancata J, Börjesson-Hanson A, Ostling S, Sjögren K, Skoog I. Diagnostic criteria influence dementia prevalence. Am J Geriatr Psychiatry 2007;15:1034-45.
Erkinjuntti T, Ostbye T, Steenhuis R, Hachinski V. The effect of different diagnostic criteria on the prevalence of dementia. N Engl J Med 1997;337:1667-74.
Jorm AF, Jolley D. The incidence of dementia: A meta-analysis. Neurology 1998;51:728-33.
Gold G, Giannakopoulos P, Montes-Paixao Júnior C, Herrmann FR, Mulligan R, Michel JP, et al.
Sensitivity and specificity of newly proposed clinical criteria for possible vascular dementia. Neurology 1997;49:690-4.
Bachman DL, Wolf PA, Linn RT, Knoefel JE, Cobb JL, Belanger AJ, et al.
Incidence of dementia and probable Alzheimer's disease in a general population: The Framingham Study. Neurology 1993;43(3 Pt 1):515-9.
Corrada MM, Brookmeyer R, Paganini-Hill A, Berlau D, Kawas CH. Dementia incidence continues to increase with age in the oldest old: The 90+ study. Ann Neurol 2010;67:114-21.
Kukull WA, Higdon R, Bowen JD, McCormick WC, Teri L, Schellenberg GD, et al.
Dementia and Alzheimer disease incidence: A prospective cohort study. Arch Neurol 2002;59:1737-46.
Imfeld P, Brauchli Pernus YB, Jick SS, Meier CR. Epidemiology, co-morbidities, and medication use of patients with Alzheimer's disease or vascular dementia in the UK. J Alzheimers Dis 2013;35:565-73.
Fitzpatrick AL, Kuller LH, Ives DG, Lopez OL, Jagust W, Breitner JC, et al.
Incidence and prevalence of dementia in the Cardiovascular Health Study. J Am Geriatr Soc 2004;52:195-204.
Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, et al.
Vascular contributions to cognitive impairment and dementia: A statement for healthcare professionals from the american heart association/american stroke association. Stroke 2011;42:2672-713.
Gorelick PB, Pantoni L. Advances in vascular cognitive impairment. Stroke 2013;44:307-8.
Honig LS, Tang MX, Albert S, Costa R, Luchsinger J, Manly J, et al.
Stroke and the risk of Alzheimer disease. Arch Neurol 2003;60:1707-12.
Gorelick PB. Risk factors for vascular dementia and Alzheimer disease. Stroke 2004;35 11 Suppl 1:2620-2.
Beeri MS, Ravona-Springer R, Silverman JM, Haroutunian V. The effects of cardiovascular risk factors on cognitive compromise. Dialogues Clin Neurosci 2009;11:201-12.
Mielke MM, Rosenberg PB, Tschanz J, Cook L, Corcoran C, Hayden KM, et al.
Vascular factors predict rate of progression in Alzheimer disease. Neurology 2007;69:1850-8.
Dichgans M, Zietemann V. Prevention of vascular cognitive impairment. Stroke 2012;43:3137-46.
Craft S. The role of metabolic disorders in Alzheimer disease and vascular dementia: Two roads converged. Arch Neurol 2009;66:300-5.
Sharp SI, Aarsland D, Day S, Sønnesyn H; Alzheimer's Society Vascular Dementia Systematic Review Group, Ballard C. Hypertension is a potential risk factor for vascular dementia: Systematic review. Int J Geriatr Psychiatry 2011;26:661-9.
Luck T, Riedel-Heller SG, Luppa M, Wiese B, Wollny A, Wagner M, et al.
Risk factors for incident mild cognitive impairment – Results from the German Study on Ageing, Cognition and Dementia in Primary Care Patients (AgeCoDe). Acta Psychiatr Scand 2010;121:260-72.
Waldstein SR, Giggey PP, Thayer JF, Zonderman AB. Nonlinear relations of blood pressure to cognitive function: The Baltimore Longitudinal Study of Aging. Hypertension 2005;45:374-9.
Meyer JS, Rauch G, Rauch RA, Haque A. Risk factors for cerebral hypoperfusion, mild cognitive impairment, and dementia. Neurobiol Aging 2000;21:161-9.
Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol 2005;4:487-99.
Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, Babeanu S, et al.
The prevention of dementia with antihypertensive treatment: New evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 2002;162:2046-52.
Ahtiluoto S, Polvikoski T, Peltonen M, Solomon A, Tuomilehto J, Winblad B, et al.
Diabetes, Alzheimer disease, and vascular dementia: A population-based neuropathologic study. Neurology 2010;75:1195-202.
Schnaider Beeri M, Goldbourt U, Silverman JM, Noy S, Schmeidler J, Ravona-Springer R, et al.
Diabetes mellitus in midlife and the risk of dementia three decades later. Neurology 2004;63:1902-7.
Kawamura T, Umemura T, Hotta N. Cognitive impairment in diabetic patients: Can diabetic control prevent cognitive decline? J Diabetes Investig 2012;3:413-23.
Christman AL, Matsushita K, Gottesman RF, Mosley T, Alonso A, Coresh J, et al.
Glycated haemoglobin and cognitive decline: The Atherosclerosis Risk in Communities (ARIC) study. Diabetologia 2011;54:1645-52.
Suryadevara V, Storey SG, Aronow WS, Ahn C. Association of abnormal serum lipids in elderly persons with atherosclerotic vascular disease and dementia, atherosclerotic vascular disease without dementia, dementia without atherosclerotic vascular disease, and no dementia or atherosclerotic vascular disease. J Gerontol A Biol Sci Med Sci 2003;58:M859-61.
Anstey KJ, Lipnicki DM, Low LF. Cholesterol as a risk factor for dementia and cognitive decline: A systematic review of prospective studies with meta-analysis. Am J Geriatr Psychiatry 2008;16:343-54.
Tsivgoulis G, Judd S, Letter AJ, Alexandrov AV, Howard G, Nahab F, et al.
Adherence to a Mediterranean diet and risk of incident cognitive impairment. Neurology 2013;80:1684-92.
Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet 2000;356:1627-31.
Trompet S, van Vliet P, de Craen AJ, Jolles J, Buckley BM, Murphy MB, et al.
Pravastatin and cognitive function in the elderly. Results of the PROSPER study. J Neurol 2010;257:85-90.
Ravaglia G, Forti P, Maioli F, Chiappelli M, Montesi F, Tumini E, et al.
Blood inflammatory markers and risk of dementia: The Conselice Study of Brain Aging. Neurobiol Aging 2007;28:1810-20.
Engelhart MJ, Geerlings MI, Meijer J, Kiliaan A, Ruitenberg A, van Swieten JC, et al.
Inflammatory proteins in plasma and the risk of dementia: The rotterdam study. Arch Neurol 2004;61:668-72.
Ruitenberg A, Ott A, van Swieten JC, Hofman A, Breteler MM. Incidence of dementia: Does gender make a difference? Neurobiol Aging 2001;22:575-80.
Eichner JE, Dunn ST, Perveen G, Thompson DM, Stewart KE, Stroehla BC. Apolipoprotein E polymorphism and cardiovascular disease: A HuGE review. Am J Epidemiol 2002;155:487-95.
Heun R, Gühne U, Luck T, Angermeyer MC, Ueberham U, Potluri R, et al.
Apolipoprotein E allele 4 is not a sufficient or a necessary predictor of the development of mild cognitive impairment. Eur Psychiatry 2010;25:15-8.
EClipSE Collaborative Members, Brayne C, Ince PG, Keage HA, McKeith IG, Matthews FE, et al.
Education, the brain and dementia: Neuroprotection or compensation? Brain 2010;133(Pt 8):2210-6.
Verdelho A, Madureira S, Ferro JM, Baezner H, Blahak C, Poggesi A, et al.
Physical activity prevents progression for cognitive impairment and vascular dementia: Results from the LADIS (leukoaraiosis and disability) study. Stroke 2012;43:3331-5.
Anstey KJ, von Sanden C, Salim A, O'Kearney R. Smoking as a risk factor for dementia and cognitive decline: A meta-analysis of prospective studies. Am J Epidemiol 2007;166:367-78.
Peters R, Peters J, Warner J, Beckett N, Bulpitt C. Alcohol, dementia and cognitive decline in the elderly: A systematic review. Age Ageing 2008;37:505-12.
Fitzpatrick AL, Kuller LH, Lopez OL, Diehr P, O'Meara ES, Longstreth WT Jr., et al.
Midlife and late-life obesity and the risk of dementia: Cardiovascular health study. Arch Neurol 2009;66:336-42.
Kurella Tamura M, Yaffe K. Dementia and cognitive impairment in ESRD: Diagnostic and therapeutic strategies. Kidney Int 2011;79:14-22.
Brouns R, De Deyn PP. Neurological complications in renal failure: A review. Clin Neurol Neurosurg 2004;107:1-16.
Vidal JS, Sigurdsson S, Jonsdottir MK, Eiriksdottir G, Thorgeirsson G, Kjartansson O, et al.
Coronary artery calcium, brain function and structure: The AGES-Reykjavik Study. Stroke 2010;41:891-7.
Bunch TJ, Weiss JP, Crandall BG, May HT, Bair TL, Osborn JS, et al.
Atrial fibrillation is independently associated with senile, vascular, and Alzheimer's dementia. Heart Rhythm 2010;7:433-7.
Laurin D, Masaki KH, White LR, Launer LJ. Ankle-to-brachial index and dementia: The Honolulu-Asia Aging Study. Circulation 2007;116:2269-74.
Jefferson AL, Himali JJ, Beiser AS, Au R, Massaro JM, Seshadri S, et al.
Cardiac index is associated with brain aging: The Framingham Heart Study. Circulation 2010;122:690-7.
del Ser T, Barba R, Morin MM, Domingo J, Cemillan C, Pondal M, et al.
Evolution of cognitive impairment after stroke and risk factors for delayed progression. Stroke 2005;36:2670-5.
Desmond DW, Moroney JT, Paik MC, Sano M, Mohr JP, Aboumatar S, et al.
Frequency and clinical determinants of dementia after ischemic stroke. Neurology 2000;54:1124-31.
Kokmen E, Whisnant JP, O'Fallon WM, Chu CP, Beard CM. Dementia after ischemic stroke: A population-based study in Rochester, Minnesota (1960-1984). Neurology 1996;46:154-9.
Béjot Y, Aboa-Eboulé C, Durier J, Rouaud O, Jacquin A, Ponavoy E, et al.
Prevalence of early dementia after first-ever stroke: A 24-year population-based study. Stroke 2011;42:607-12.
Ivan CS, Seshadri S, Beiser A, Au R, Kase CS, Kelly-Hayes M, et al.
Dementia after stroke: The Framingham Study. Stroke 2004;35:1264-8.
Altieri M, Di Piero V, Pasquini M, Gasparini M, Vanacore N, Vicenzini E, et al.
Delayed poststroke dementia: A 4-year follow-up study. Neurology 2004;62:2193-7.
Rasquin SM, Lodder J, Ponds RW, Winkens I, Jolles J, Verhey FR. Cognitive functioning after stroke: A one-year follow-up study. Dement Geriatr Cogn Disord 2004;18:138-44.
de Haan EH, Nys GM, Van Zandvoort MJ. Cognitive function following stroke and vascular cognitive impairment. Curr Opin Neurol 2006;19:559-64.
Chaudhari TS, Verma R, Garg RK, Singh MK, Malhotra HS, Sharma PK. Clinico-radiological predictors of vascular cognitive impairment (VCI) in patients with stroke: A prospective observational study. J Neurol Sci 2014;340:150-8.
Narasimhalu K, Ang S, De Silva DA, Wong MC, Chang HM, Chia KS, et al.
Severity of CIND and MCI predict incidence of dementia in an ischemic stroke cohort. Neurology 2009;73:1866-72.
Desmond DW, Moroney JT, Sano M, Stern Y. Incidence of dementia after ischemic stroke: Results of a longitudinal study. Stroke 2002;33:2254-60.
Leys D, Hénon H, Mackowiak-Cordoliani MA, Pasquier F. Poststroke dementia. Lancet Neurol 2005;4:752-9.
Lin JH, Lin RT, Tai CT, Hsieh CL, Hsiao SF, Liu CK. Prediction of poststroke dementia. Neurology 2003;61:343-8.
Srikanth VK, Quinn SJ, Donnan GA, Saling MM, Thrift AG. Long-term cognitive transitions, rates of cognitive change, and predictors of incident dementia in a population-based first-ever stroke cohort. Stroke 2006;37:2479-83.
Tatemichi TK, Desmond DW, Stern Y, Paik M, Sano M, Bagiella E. Cognitive impairment after stroke: Frequency, patterns, and relationship to functional abilities. J Neurol Neurosurg Psychiatry 1994;57:202-7.
Zhu L, Fratiglioni L, Guo Z, Winblad B, Viitanen M. Incidence of stroke in relation to cognitive function and dementia in the Kungsholmen Project. Neurology 2000;54:2103-7.
DeFries T, Avendaño M, Glymour MM. Level and change in cognitive test scores predict risk of first stroke. J Am Geriatr Soc 2009;57:499-505.
Imfeld P, Bodmer M, Schuerch M, Jick SS, Meier CR. Risk of incident stroke in patients with Alzheimer disease or vascular dementia. Neurology 2013;81:910-9.
Gottesman RF, Hillis AE. Predictors and assessment of cognitive dysfunction resulting from ischaemic stroke. Lancet Neurol 2010;9:895-905.
Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003;348:1215-22.
Saczynski JS, Beiser A, Seshadri S, Auerbach S, Wolf PA, Au R. Depressive symptoms and risk of dementia: The Framingham Heart Study. Neurology 2010;75:35-41.
Gao Y, Huang C, Zhao K, Ma L, Qiu X, Zhang L, et al
. Depression as a risk factor for dementia and mild cognitive impairment: A meta-analysis of longitudinal studies. Int J Geriatr Psychiatry 2013;28:441-9.
Köhler S, van Boxtel M, Jolles J, Verhey F. Depressive symptoms and risk for dementia: A 9-year follow-up of the Maastricht Aging Study. Am J Geriatr Psychiatry 2011;19:902-5.
Bennett S, Thomas AJ. Depression and dementia: Cause, consequence or coincidence? Maturitas 2014;79:184-90.
Enache D, Winblad B, Aarsland D. Depression in dementia: Epidemiology, mechanisms, and treatment. Curr Opin Psychiatry 2011;24:461-72.
Butters MA, Young JB, Lopez O, Aizenstein HJ, Mulsant BH, Reynolds CF 3rd
, et al.
Pathways linking late-life depression to persistent cognitive impairment and dementia. Dialogues Clin Neurosci 2008;10:345-57.
Allan LM, Rowan EN, Thomas AJ, Polvikoski TM, O'Brien JT, Kalaria RN. Long-term incidence of depression and predictors of depressive symptoms in older stroke survivors. Br J Psychiatry 2013;203:453-60.
Barnes DE, Yaffe K, Byers AL, McCormick M, Schaefer C, Whitmer RA. Midlife vs. late-life depressive symptoms and risk of dementia: Differential effects for Alzheimer disease and vascular dementia. Arch Gen Psychiatry 2012;69:493-8.
Brommelhoff JA, Gatz M, Johansson B, McArdle JJ, Fratiglioni L, Pedersen NL. Depression as a risk factor or prodromal feature for dementia? Findings in a population-based sample of Swedish twins. Psychol Aging 2009;24:373-84.
Li G, Wang LY, Shofer JB, Thompson ML, Peskind ER, McCormick W, et al.
Temporal relationship between depression and dementia: Findings from a large community-based 15-year follow-up study. Arch Gen Psychiatry 2011;68:970-7.
Lenoir H, Dufouil C, Auriacombe S, Lacombe JM, Dartigues JF, Ritchie K, et al.
Depression history, depressive symptoms, and incident dementia: The 3C Study. J Alzheimers Dis 2011;26:27-38.
Panza F, Frisardi V, Capurso C, D'Introno A, Colacicco AM, Imbimbo BP, et al.
Late-life depression, mild cognitive impairment, and dementia: Possible continuum? Am J Geriatr Psychiatry 2010;18:98-116.
Dotson VM, Beydoun MA, Zonderman AB. Recurrent depressive symptoms and the incidence of dementia and mild cognitive impairment. Neurology 2010;75:27-34.
Richard E, Reitz C, Honig LH, Schupf N, Tang MX, Manly JJ, et al.
Late-life depression, mild cognitive impairment, and dementia. JAMA Neurol 2013;70:374-82.
da Silva J, Gonçalves-Pereira M, Xavier M, Mukaetova-Ladinska EB. Affective disorders and risk of developing dementia: Systematic review. Br J Psychiatry 2013;202:177-86.
Chen PL, Wang PY, Sheu WH, Chen YT, Ho YP, Hu HH, et al.
Changes of brachial flow-mediated vasodilation in different ischemic stroke subtypes. Neurology 2006;67:1056-8.
Janssen J, Hulshoff Pol HE, de Leeuw FE, Schnack HG, Lampe IK, Kok RM, et al.
Hippocampal volume and subcortical white matter lesions in late life depression: Comparison of early and late onset depression. J Neurol Neurosurg Psychiatry 2007;78:638-40.
Thomas AJ, O'Brien JT. Depression and cognition in older adults. Curr Opin Psychiatry 2008;21:8-13.
Köhler S, Thomas AJ, Lloyd A, Barber R, Almeida OP, O'Brien JT. White matter hyperintensities, cortisol levels, brain atrophy and continuing cognitive deficits in late-life depression. Br J Psychiatry 2010;196:143-9.
Teodorczuk A, O'Brien JT, Firbank MJ, Pantoni L, Poggesi A, Erkinjuntti T, et al.
White matter changes and late-life depressive symptoms: Longitudinal study. Br J Psychiatry 2007;191:212-7.
Baldwin RC, O'Brien J. Vascular basis of late-onset depressive disorder. Br J Psychiatry 2002;180:157-60.
Liebetrau M, Steen B, Skoog I. Depression as a risk factor for the incidence of first-ever stroke in 85-year-olds. Stroke 2008;39:1960-5.
Ganguli M, Du Y, Dodge HH, Ratcliff GG, Chang CC. Depressive symptoms and cognitive decline in late life: A prospective epidemiological study. Arch Gen Psychiatry 2006;63:153-60.
Luppa M, Luck T, Ritschel F, Angermeyer MC, Villringer A, Riedel-Heller SG. Depression and incident dementia. An 8-year population-based prospective study. PLoS One 2013;8:e59246.
Sheline YI, Barch DM, Garcia K, Gersing K, Pieper C, Welsh-Bohmer K, et al.
Cognitive function in late life depression: Relationships to depression severity, cerebrovascular risk factors and processing speed. Biol Psychiatry 2006;60:58-65.
Rapp MA, Schnaider-Beeri M, Wysocki M, Guerrero-Berroa E, Grossman HT, Heinz A, et al.
Cognitive decline in patients with dementia as a function of depression. Am J Geriatr Psychiatry 2011;19:357-63.
Nelson JC, Devanand DP. A systematic review and meta-analysis of placebo-controlled antidepressant studies in people with depression and dementia. J Am Geriatr Soc 2011;59:577-85.
Bains J, Birks J, Dening T. Antidepressants for treating depression in dementia. Cochrane Database Syst Rev 2002:CD003944.
Román GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al.
Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43:250-60.
Kanekar S, Poot JD. Neuroimaging of vascular dementia. Radiol Clin North Am 2014;52:383-401.
Theysohn JM, Kraff O, Maderwald S, Barth M, Ladd SC, Forsting M, et al.
7 tesla MRI of microbleeds and white matter lesions as seen in vascular dementia. J Magn Reson Imaging 2011;33:782-91.
Fernando MS, Simpson JE, Matthews F, Brayne C, Lewis CE, Barber R, et al.
White matter lesions in an unselected cohort of the elderly: Molecular pathology suggests origin from chronic hypoperfusion injury. Stroke 2006;37:1391-8.
van Dijk EJ, Breteler MM, Schmidt R, Berger K, Nilsson LG, Oudkerk M, et al.
The association between blood pressure, hypertension, and cerebral white matter lesions: Cardiovascular determinants of dementia study. Hypertension 2004;44:625-30.
Wen W, Sachdev PS. Extent and distribution of white matter hyperintensities in stroke patients: The Sydney Stroke Study. Stroke 2004;35:2813-9.
Atwood LD, Wolf PA, Heard-Costa NL, Massaro JM, Beiser A, D'Agostino RB, et al.
Genetic variation in white matter hyperintensity volume in the Framingham Study. Stroke 2004;35:1609-13.
Au R, Massaro JM, Wolf PA, Young ME, Beiser A, Seshadri S, et al.
Association of white matter hyperintensity volume with decreased cognitive functioning: The Framingham Heart Study. Arch Neurol 2006;63:246-50.
Price CC, Mitchell SM, Brumback B, Tanner JJ, Schmalfuss I, Lamar M, et al.
MRI-leukoaraiosis thresholds and the phenotypic expression of dementia. Neurology 2012;79:734-40.
de Groot JC, de Leeuw FE, Oudkerk M, van Gijn J, Hofman A, Jolles J, et al.
Cerebral white matter lesions and cognitive function: The Rotterdam Scan Study. Ann Neurol 2000;47:145-51.
Prins ND, van Dijk EJ, den Heijer T, Vermeer SE, Koudstaal PJ, Oudkerk M, et al.
Cerebral white matter lesions and the risk of dementia. Arch Neurol 2004;61:1531-4.
Black S, Gao F, Bilbao J. Understanding white matter disease: Imaging-pathological correlations in vascular cognitive impairment. Stroke 2009;40 3 Suppl: S48-52.
Wahlund LO, Barkhof F, Fazekas F, Bronge L, Augustin M, Sjögren M, et al.
A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 2001;32:1318-22.
Kapeller P, Barber R, Vermeulen RJ, Adèr H, Scheltens P, Freidl W, et al.
Visual rating of age-related white matter changes on magnetic resonance imaging: Scale comparison, interrater agreement, and correlations with quantitative measurements. Stroke 2003;34:441-5.
Smith EE, Schneider JA, Wardlaw JM, Greenberg SM. Cerebral microinfarcts: The invisible lesions. Lancet Neurol 2012;11:272-82.
Arvanitakis Z, Leurgans SE, Barnes LL, Bennett DA, Schneider JA. Microinfarct pathology, dementia, and cognitive systems. Stroke 2011;42:722-7.
Reed BR, Eberling JL, Mungas D, Weiner M, Kramer JH, Jagust WJ. Effects of white matter lesions and lacunes on cortical function. Arch Neurol 2004;61:1545-50.
Prins ND, van Dijk EJ, den Heijer T, Vermeer SE, Jolles J, Koudstaal PJ, et al.
Cerebral small-vessel disease and decline in information processing speed, executive function and memory. Brain 2005;128(Pt 9):2034-41.
Carey CL, Kramer JH, Josephson SA, Mungas D, Reed BR, Schuff N, et al.
Subcortical lacunes are associated with executive dysfunction in cognitively normal elderly. Stroke 2008;39:397-402.
Jokinen H, Gouw AA, Madureira S, Ylikoski R, van Straaten EC, van der Flier WM, et al.
Incident lacunes influence cognitive decline: The LADIS study. Neurology 2011;76:1872-8.
Kalaria RN, Kenny RA, Ballard CG, Perry R, Ince P, Polvikoski T. Towards defining the neuropathological substrates of vascular dementia. J Neurol Sci 2004;226:75-80.
Boon A, Lodder J, Heuts-van Raak L, Kessels F. Silent brain infarcts in 755 consecutive patients with a first-ever supratentorial ischemic stroke. Relationship with index-stroke subtype, vascular risk factors, and mortality. Stroke 1994;25:2384-90.
Nishio Y, Hashimoto M, Ishii K, Mori E. Neuroanatomy of a neurobehavioral disturbance in the left anterior thalamic infarction. J Neurol Neurosurg Psychiatry 2011;82:1195-200.
Derdeyn CP, Khosla A, Videen TO, Fritsch SM, Carpenter DL, Grubb RL Jr., et al.
Severe hemodynamic impairment and border zone – Region infarction. Radiology 2001;220:195-201.
Momjian-Mayor I, Baron JC. The pathophysiology of watershed infarction in internal carotid artery disease: Review of cerebral perfusion studies. Stroke 2005;36:567-77.
Saliou G, Théaudin M, Vincent CJL, Souillard-Scemama R. Watershed infarction. In: Practical Guide to Neurovascular Emergencies. Paris: Springer; 2014. p. 69-75.
Suemoto CK, Nitrini R, Grinberg LT, Ferretti RE, Farfel JM, Leite RE, et al.
Atherosclerosis and dementia: A cross-sectional study with pathological analysis of the carotid arteries. Stroke 2011;42:3614-5.
van Oijen M, de Jong FJ, Witteman JC, Hofman A, Koudstaal PJ, Breteler MM. Atherosclerosis and risk for dementia. Ann Neurol 2007;61:403-10.
Iadecola C. The pathobiology of vascular dementia. Neuron 2013;80:844-66.
Toledo JB, Arnold SE, Raible K, Brettschneider J, Xie SX, Grossman M, et al.
Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. Brain 2013;136(Pt 9):2697-706.
Quaegebeur A, Lange C, Carmeliet P. The neurovascular link in health and disease: Molecular mechanisms and therapeutic implications. Neuron 2011;71:406-24.
Brown WR, Thore CR. Review: Cerebral microvascular pathology in ageing and neurodegeneration. Neuropathol Appl Neurobiol 2011;37:56-74.
Marstrand JR, Garde E, Rostrup E, Ring P, Rosenbaum S, Mortensen EL, et al.
Cerebral perfusion and cerebrovascular reactivity are reduced in white matter hyperintensities. Stroke 2002;33:972-6.
Makedonov I, Black SE, MacIntosh BJ. Cerebral small vessel disease in aging and Alzheimer's disease: A comparative study using MRI and SPECT. Eur J Neurol 2013;20:243-50.
Matsushita K, Kuriyama Y, Nagatsuka K, Nakamura M, Sawada T, Omae T. Periventricular white matter lucency and cerebral blood flow autoregulation in hypertensive patients. Hypertension 1994;23:565-8.
O'Sullivan M, Lythgoe DJ, Pereira AC, Summers PE, Jarosz JM, Williams SC, et al.
Patterns of cerebral blood flow reduction in patients with ischemic leukoaraiosis. Neurology 2002;59:321-6.
Ruitenberg A, den Heijer T, Bakker SL, van Swieten JC, Koudstaal PJ, Hofman A, et al.
Cerebral hypoperfusion and clinical onset of dementia: The Rotterdam Study. Ann Neurol 2005;57:789-94.
Brisset M, Boutouyrie P, Pico F, Zhu Y, Zureik M, Schilling S, et al.
Large-vessel correlates of cerebral small-vessel disease. Neurology 2013;80:662-9.
Taheri S, Gasparovic C, Huisa BN, Adair JC, Edmonds E, Prestopnik J, et al.
Blood-brain barrier permeability abnormalities in vascular cognitive impairment. Stroke 2011;42:2158-63.
Hermann P, Romero C, Schmidt C, Reis C, Zerr I. CSF biomarkers and neuropsychological profiles in patients with cerebral small-vessel disease. PLoS One 2014;9:e105000.
Topakian R, Barrick TR, Howe FA, Markus HS. Blood-brain barrier permeability is increased in normal-appearing white matter in patients with lacunar stroke and leucoaraiosis. J Neurol Neurosurg Psychiatry 2010;81:192-7.
Back SA, Kroenke CD, Sherman LS, Lawrence G, Gong X, Taber EN, et al.
White matter lesions defined by diffusion tensor imaging in older adults. Ann Neurol 2011;70:465-76.
Cohen RA, Tong X. Vascular oxidative stress: The common link in hypertensive and diabetic vascular disease. J Cardiovasc Pharmacol 2010;55:308-16.
Kazama K, Anrather J, Zhou P, Girouard H, Frys K, Milner TA, et al.
Angiotensin II impairs neurovascular coupling in neocortex through NADPH oxidase-derived radicals. Circ Res 2004;95:1019-26.
Nitkunan A, Lanfranconi S, Charlton RA, Barrick TR, Markus HS. Brain atrophy and cerebral small vessel disease: A prospective follow-up study. Stroke 2011;42:133-8.
Franklin RJ, Ffrench-Constant C. Remyelination in the CNS: From biology to therapy. Nat Rev Neurosci 2008;9:839-55.
Román GC, Kalaria RN. Vascular determinants of cholinergic deficits in Alzheimer disease and vascular dementia. Neurobiol Aging 2006;27:1769-85.
Schaefer A, Quinque EM, Kipping JA, Arélin K, Roggenhofer E, Frisch S, et al.
Early small vessel disease affects frontoparietal and cerebellar hubs in close correlation with clinical symptoms – A resting-state fMRI study. J Cereb Blood Flow Metab 2014;34:1091-5.
Jellinger KA. Pathology and pathogenesis of vascular cognitive impairment – A critical update. Front Aging Neurosci 2013;5:17.
Thal DR, Grinberg LT, Attems J. Vascular dementia: Different forms of vessel disorders contribute to the development of dementia in the elderly brain. Exp Gerontol 2012;47:816-24.
van Norden AG, van Uden IW, de Laat KF, Gons RA, Kessels RP, van Dijk EJ, et al.
Cerebral microbleeds are related to subjective cognitive failures: The RUN DMC study. Neurobiol Aging 2013;34:2225-30.
Balestrini S, Perozzi C, Altamura C, Vernieri F, Luzzi S, Bartolini M, et al.
Severe carotid stenosis and impaired cerebral hemodynamics can influence cognitive deterioration. Neurology 2013;80:2145-50.
Marshall RS, Festa JR, Cheung YK, Chen R, Pavol MA, Derdeyn CP, et al.
Cerebral hemodynamics and cognitive impairment: Baseline data from the RECON trial. Neurology 2012;78:250-5.
Alosco ML, Brickman AM, Spitznagel MB, Garcia SL, Narkhede A, Griffith EY, et al.
Cerebral perfusion is associated with white matter hyperintensities in older adults with heart failure. Congest Heart Fail 2013;19:E29-34.
Freitas S, Simões MR, Alves L, Duro D, Santana I. Montreal Cognitive Assessment (MoCA): Validation study for frontotemporal dementia. J Geriatr Psychiatry Neurol 2012;25:146-54.
Erkinjuntti T. Subcortical vascular dementia. Cerebrovasc Dis 2002;13 Suppl 2:58-60.
Staekenborg SS, Su T, van Straaten EC, Lane R, Scheltens P, Barkhof F, et al.
Behavioural and psychological symptoms in vascular dementia; differences between small- and large-vessel disease. J Neurol Neurosurg Psychiatry 2010;81:547-51.
Tomimoto H. Subcortical vascular dementia. Neurosci Res 2011;71:193-9.
Chui HC. Subcortical ischemic vascular dementia. Neurol Clin 2007;25:717-40, vi.
Simonsen AH, Hagnelius NO, Waldemar G, Nilsson TK, McGuire J. Protein markers for the differential diagnosis of vascular dementia and Alzheimer's disease. Int J Proteomics 2012;2012:824024.
Jagtap A, Gawande S, Sharma S. Biomarkers in vascular dementia: A recent update Biomarkers Genomic Med 2015;7:43-56.
Shoji M. Biomarkers of the dementia. Int J Alzheimers Dis 2011;2011:564321.
Paraskevas GP, Kapaki E, Papageorgiou SG, Kalfakis N, Andreadou E, Zalonis I, et al.
CSF biomarker profile and diagnostic value in vascular dementia. Eur J Neurol 2009;16:205-11.
Berglund L, Ramakrishnan R. Lipoprotein(a): An elusive cardiovascular risk factor. Arterioscler Thromb Vasc Biol 2004;24:2219-26.
Hamaguchi T, Yamada M. Genetic factors for cerebral amyloid angiopathy. Brain Nerve 2008;60:1275-83.
Hachinski VC, Iliff LD, Zilhka E, Du Boulay GH, McAllister VL, Marshall J, et al.
Cerebral blood flow in dementia. Arch Neurol 1975;32:632-7.
Moroney JT, Bagiella E, Desmond DW, Hachinski VC, Mölsä PK, Gustafson L, et al.
Meta-analysis of the Hachinski Ischemic Score in pathologically verified dementias. Neurology 1997;49:1096-105.
Chui HC, Mack W, Jackson JE, Mungas D, Reed BR, Tinklenberg J, et al.
Clinical criteria for the diagnosis of vascular dementia: A multicenter study of comparability and interrater reliability. Arch Neurol 2000;57:191-6.
Wetterling T, Kanitz RD, Borgis KJ. Comparison of different diagnostic criteria for vascular dementia (ADDTC, DSM-IV, ICD-10, NINDS-AIREN). Stroke 1996;27:30-6.
Lopez OL, Kuller LH, Becker JT, Jagust WJ, DeKosky ST, Fitzpatrick A, et al.
Classification of vascular dementia in the Cardiovascular Health Study Cognition Study. Neurology 2005;64:1539-47.
Pohjasvaara T, Erkinjuntti T, Vataja R, Kaste M. Dementia three months after stroke. Baseline frequency and effect of different definitions of dementia in the Helsinki Stroke Aging Memory Study (SAM) cohort. Stroke 1997;28:785-92.
Godefroy O; GRECOG-VASC Study Group, Leclercq C, Bugnicourt JM, Roussel M, Moroni C, Quaglino V, et al.
Neuropsychological assessment and cerebral vascular disease: The new standards. Rev Neurol (Paris) 2013;169:779-85.
Vasquez BP, Zakzanis KK. The neuropsychological profile of vascular cognitive impairment not demented: A meta-analysis. J Neuropsychol 2015;9:109-36.
Yoon CW, Shin JS, Kim HJ, Cho H, Noh Y, Kim GH, et al.
Cognitive deficits of pure subcortical vascular dementia vs. Alzheimer disease: PiB-PET-based study. Neurology 2013;80:569-73.
Román GC. Vascular dementia: Distinguishing characteristics, treatment, and prevention. J Am Geriatr Soc 2003;51 5 Suppl 2:S296-304.
Sachdev PS, Brodaty H, Valenzuela MJ, Lorentz L, Looi JC, Wen W, et al.
The neuropsychological profile of vascular cognitive impairment in stroke and TIA patients. Neurology 2004;62:912-9.
Gu J, Fischer CE, Saposnik G, Schweizer TA. Profile of cognitive complaints in vascular mild cognitive impairment and mild cognitive impairment. ISRN Neurol 2013;2013:865827.
Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al.
The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005;53:695-9.
Ihara M, Okamoto Y, Takahashi R. Suitability of the Montreal cognitive assessment versus the mini-mental state examination in detecting vascular cognitive impairment. J Stroke Cerebrovasc Dis 2013;22:737-41.
Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-14.
Johnson N, Barion A, Rademaker A, Rehkemper G, Weintraub S. The Activities of Daily Living questionnaire: A validation study in patients with dementia. Alzheimer Dis Assoc Disord 2004;18:223-30.
Tomimoto H, Ohtani R, Shibata M, Nakamura N, Ihara M. Loss of cholinergic pathways in vascular dementia of the Binswanger type. Dement Geriatr Cogn Disord 2005;19:282-8.
Gorelick PB, Bowler JV. Advances in vascular cognitive impairment 2007. Stroke 2008;39:279-82.
Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Rivastigmine in subcortical vascular dementia: An open 22-month study. J Neurol Sci 2002;203-204:141-6.
Orgogozo JM, Rigaud AS, Stöffler A, Möbius HJ, Forette F. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: A randomized, placebo-controlled trial (MMM 300). Stroke 2002;33:1834-9.
Pantoni L, del Ser T, Soglian AG, Amigoni S, Spadari G, Binelli D, et al.
Efficacy and safety of nimodipine in subcortical vascular dementia: A randomized placebo-controlled trial. Stroke 2005;36:619-24.
Skoog I, Korczyn AD, Guekht A. Neuroprotection in vascular dementia: A future path. J Neurol Sci 2012;322:232-6.
Rands G, Orrell M. Aspirin for vascular dementia. Cochrane Libr 2000.
Korczyn AD, Brainin M, Guekht A. Neuroprotection in ischemic stroke: What does the future hold? Expert Rev Neurother 2015;15:227-9.
Araújo JR, Martel F, Borges N, Araújo JM, Keating E. Folates and aging: Role in mild cognitive impairment, dementia and depression. Ageing Res Rev 2015;22:9-19.
[Table 1], [Table 2], [Table 3], [Table 4]